Case Studies
Forecasting a Commercially Viable T Cell Therapy Manufacturing Process
In this case study, a company requested help from ScaleReady to build business case for G-Rex®500M-CS bioreactors as the primary cell production platform for their autologous TCR T cell therapy pipeline. ScaleReady modeled operational costs
for an autologous TCR T cell therapy company using G-Rex bioreactors. This provided transparency into long-term commercial
viability of the ScaleReady platform.
Case Studies
GMP Cytokines Optimization for Closed System T Cell Therapy Manufacturing
In this case study, a company focused on autologous T cell therapies targeting solid tumor cancers was progressing into clinical trials and needed to transition from research-grade to GMP-grade cytokines. Concurrently they wanted to improve
their methods of cytokine supplementation to reduce cytokine waste, improve dose accuracy across lots, and
reduce process risk by defining methods for closed-system cytokine addition. ScaleReady detailed a plan to help them achieve these goals.
Videos
Future of T Cell Manufacturing using G-Rex Closed-system
This video animation demonstrates a vision toward the industrialization and automation of T cell therapy manufacturing using G-Rex Bioreactors.
Video was created by Wilson Wolf Manufacturing Corporation.
Literature
G-Rex Closed-system Bioreactors
In this brochure you will learn how G-Rex bioreactors solve the limitations of flask and bag-based cell therapy manufacturing. In this brochure:
- G-Rex Bioreactor mechanism of action
- Benefits for cell therapy manufacturing
- GatheRex Cell Harvest Pump
- User testimonials
Videos
G-Rex – Revolutionizing Cell Therapy Manufacturing
In this video you will learn how G-Rex solve the limitations of flask and bag-based cell therapy manufacturing. By providing cells with uninterrupted access to oxygen and nutrients, the G-Rex cell culture device is the only accessible cell expansion technology that linearly scales to meet the demands of cell therapy manufacturers.
Videos
On Demand Symposium: Defining Intelligent Scale-up and Scale-out
In this recorded symposium, cell therapy manufacturing leaders speak about defining and planning for intelligent commercial scale up and scale out. Recorded at ISCT 2021.
Literature
TcBuster Non-viral Genetic Engineering Flyer
TcBuster non-viral gene editing solves the bottlenecks facing viral vector-based editing, including supply chain, manufacturing time, and integration safety. In this flyer:
- How TcBuster works
- Comparison to viral tranduction
- Data on transposition efficiency and scalability
Literature
ExCellerate Media for Immune Cells
This flyer provides details and data for our T cell and NK cell versions of ExCellerate media.
Videos
Evolution of Tumor-specific T Cell Production
This video features Juan Vera, Chief Development Officer at Marker Therapeutics, discussing how Marker used G-Rex Bioreactors and the Lovo Cell Processing System to evolve and simplify manufacturing of its multiple tumor-associated antigen (MultiTAA) T cell therapy in anticipation of commercialization.
This ScaleReady-sponsored seminar originally aired at the CAR-TCR Virtual 2021 Conference (Hanson Wade) on September 1st, 2021.
This ScaleReady-sponsored seminar originally aired at the CAR-TCR Virtual 2021 Conference (Hanson Wade) on September 1st, 2021.
Scientific Posters
Determining Optimal Seeding Density for Human T Cell Expansion in G-Rex
This scientific poster investigates the kinetics of human T cell expansion in small scale G-Rex6M bioreactors using ScaleReady reagents. Data show the affect of seeding density on fold expansion, total cell yield, and phenotypic phenotypic composition of expanded T cells, including total and memory CD4+ and CD8+ cells.